NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.4490 -0.01 (-2.18 %) (As of 07/15/2018 04:00 PM ET)Previous Close$0.4490Today's Range$0.4351 - $0.469952-Week Range$0.38 - $0.92Volume248,982 shsAverage Volume683,007 shsMarket Capitalization$308.37 millionP/E RatioN/ADividend YieldN/ABeta0.97 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Receive PLX News and Ratings via Email Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolNYSEAMERICAN:PLX CUSIPN/A Webwww.protalix.com Phone+972-4-9028100 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares145,570,000Market Cap$308.37 Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions What is Protalix Biotherapeutics' stock symbol? Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX." How were Protalix Biotherapeutics' earnings last quarter? Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The firm had revenue of $4.55 million for the quarter, compared to analyst estimates of $4.40 million. During the same period in the prior year, the firm posted ($0.48) earnings per share. View Protalix Biotherapeutics' Earnings History. What price target have analysts set for PLX? 1 Wall Street analysts have issued 12 month price objectives for Protalix Biotherapeutics' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,013.6% from the stock's current price. View Analyst Ratings for Protalix Biotherapeutics. What is the consensus analysts' recommendation for Protalix Biotherapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Protalix Biotherapeutics? Protalix Biotherapeutics saw a drop in short interest in June. As of June 29th, there was short interest totalling 2,042,619 shares, a drop of 15.9% from the June 15th total of 2,430,234 shares. Based on an average daily volume of 314,823 shares, the short-interest ratio is presently 6.5 days. Currently, 1.5% of the shares of the stock are short sold. View Protalix Biotherapeutics' Current Options Chain. Who are some of Protalix Biotherapeutics' key competitors? Some companies that are related to Protalix Biotherapeutics include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Neptune Technologies & Bioressources (NEPT) and Monash IVF Group (MVF). Who are Protalix Biotherapeutics' key executives? Protalix Biotherapeutics' management team includes the folowing people: Mr. Moshe Manor, Chief Exec. Officer, Pres and Director (Age 62)Dr. Yoseph Shaaltiel Ph.D., Founder and Exec. VP of R&D (Age 64)Mr. Yossi Maimon CPA, MBA, Chief Financial Officer, VP, Treasurer and Sec. (Age 47)Dr. Einat Brill-Almon Ph.D., Sr. VP of Product Devel. (Age 58)Mr. Tzvi Palash, Exec. Officer (Age 61) Has Protalix Biotherapeutics been receiving favorable news coverage? News coverage about PLX stock has trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Protalix Biotherapeutics earned a news impact score of 0.19 on Accern's scale. They also assigned media coverage about the company an impact score of 45.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. How do I buy shares of Protalix Biotherapeutics? Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protalix Biotherapeutics' stock price today? One share of PLX stock can currently be purchased for approximately $0.4490. How big of a company is Protalix Biotherapeutics? Protalix Biotherapeutics has a market capitalization of $308.37 million. How can I contact Protalix Biotherapeutics? Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100. MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 89 (Vote Outperform)Underperform Votes: 93 (Vote Underperform)Total Votes: 182MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?